Acceleron stock soars on lung drug trial data

Just months after its first product was approved by the FDA, Cambridge’s Acceleron Pharma is closer to executing a one-two punch after announcing new clinical trial data this week.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.